BTIG raised the firm’s price target on Theravance Biopharma (TBPH) to $40 from $25 and keeps a Buy rating on the shares. The firm is revisiting its annualized net price for ampreloxetine in nOH and lowering standalone operating expense assumptions to better reflect a rare disease launch, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- Theravance Biopharma management to meet virtually with BTIG
- Theravance Biopharma’s Earnings Call Highlights Robust Growth
- Theravance Biopharma price target raised to $20 from $15 at H.C. Wainwright
- Theravance Biopharma: Hold Rating Amid Steady Growth and Pipeline Uncertainty
- Theravance Biopharma Reports Strong Q3 2025 Results